Dr. Stephans on Treatment for Oligometastatic Lung Cancer

Kevin Stephans, MD
Published: Tuesday, Oct 04, 2016


Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

Many patients who have metastatic disease will present with metastases all over the body—though a small percentage will present with more isolated disease, Stephans explains. The majority of most available therapies, such as systemic chemotherapy or immune chemotherapy, will address disease anywhere. However, stereotactic body radiation therapy (SBRT) has the ability to address only localized disease.

The advantage of SBRT is that there are few associated toxicities because the treatment is localized, and the disadvantage is that it is only going to address disease at that site. Regarding patient selection, younger patients with fewer sites are more likely to have a long, durable response to chemotherapy.  
 

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

Many patients who have metastatic disease will present with metastases all over the body—though a small percentage will present with more isolated disease, Stephans explains. The majority of most available therapies, such as systemic chemotherapy or immune chemotherapy, will address disease anywhere. However, stereotactic body radiation therapy (SBRT) has the ability to address only localized disease.

The advantage of SBRT is that there are few associated toxicities because the treatment is localized, and the disadvantage is that it is only going to address disease at that site. Regarding patient selection, younger patients with fewer sites are more likely to have a long, durable response to chemotherapy.  
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x